Abstract
BackgroundSince the approval of the first immune checkpoint inhibitor (ICI) targeting CTLA-4 in 2011 (ipilimumab), six others, targeting the PD-1/PD-L1, have been approved by FDA for a total of more...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
